354 related articles for article (PubMed ID: 21228900)
1. Receptor activator of nuclear factor-κB ligand and osteoprotegerin: maintaining the balance to prevent bone loss.
Trouvin AP; Goëb V
Clin Interv Aging; 2010 Nov; 5():345-54. PubMed ID: 21228900
[TBL] [Abstract][Full Text] [Related]
2. Coptisine inhibits RANKL-induced NF-κB phosphorylation in osteoclast precursors and suppresses function through the regulation of RANKL and OPG gene expression in osteoblastic cells.
Lee JW; Iwahashi A; Hasegawa S; Yonezawa T; Jeon WB; Cha BY; Nagai K; Woo JT
J Nat Med; 2012 Jan; 66(1):8-16. PubMed ID: 21656335
[TBL] [Abstract][Full Text] [Related]
3. Denosumab: RANKL inhibition in the management of bone loss.
Hamdy NA
Drugs Today (Barc); 2008 Jan; 44(1):7-21. PubMed ID: 18301800
[TBL] [Abstract][Full Text] [Related]
4. Bench to bedside: elucidation of the OPG-RANK-RANKL pathway and the development of denosumab.
Lacey DL; Boyle WJ; Simonet WS; Kostenuik PJ; Dougall WC; Sullivan JK; San Martin J; Dansey R
Nat Rev Drug Discov; 2012 May; 11(5):401-19. PubMed ID: 22543469
[TBL] [Abstract][Full Text] [Related]
5. The cross-talk between osteoclasts and osteoblasts in response to strontium treatment: involvement of osteoprotegerin.
Peng S; Liu XS; Huang S; Li Z; Pan H; Zhen W; Luk KD; Guo XE; Lu WW
Bone; 2011 Dec; 49(6):1290-8. PubMed ID: 21925296
[TBL] [Abstract][Full Text] [Related]
6. Assessment of OPG/RANK/RANKL gene expression levels in peripheral blood mononuclear cells (PBMC) after treatment with strontium ranelate and ibandronate in patients with postmenopausal osteoporosis.
Stuss M; Rieske P; Cegłowska A; Stêpień-Kłos W; Liberski PP; Brzeziańska E; Sewerynek E
J Clin Endocrinol Metab; 2013 May; 98(5):E1007-11. PubMed ID: 23543663
[TBL] [Abstract][Full Text] [Related]
7. [Molecular mechanisms of action of bisphosphonates and strontium ranelate].
Vengerovskiĭ AI; Khlusov IA; Nechaev KA
Eksp Klin Farmakol; 2014; 77(9):43-6. PubMed ID: 25365870
[TBL] [Abstract][Full Text] [Related]
8. Denosumab, a fully human monoclonal antibody to RANKL, inhibits bone resorption and increases BMD in knock-in mice that express chimeric (murine/human) RANKL.
Kostenuik PJ; Nguyen HQ; McCabe J; Warmington KS; Kurahara C; Sun N; Chen C; Li L; Cattley RC; Van G; Scully S; Elliott R; Grisanti M; Morony S; Tan HL; Asuncion F; Li X; Ominsky MS; Stolina M; Dwyer D; Dougall WC; Hawkins N; Boyle WJ; Simonet WS; Sullivan JK
J Bone Miner Res; 2009 Feb; 24(2):182-95. PubMed ID: 19016581
[TBL] [Abstract][Full Text] [Related]
9. Discovery of the RANKL/RANK/OPG system.
Yasuda H
J Bone Miner Metab; 2021 Jan; 39(1):2-11. PubMed ID: 33389131
[TBL] [Abstract][Full Text] [Related]
10. Updates on the role of receptor activator of nuclear factor κB/receptor activator of nuclear factor κB ligand/osteoprotegerin pathway in breast cancer risk and treatment.
Bayer CM; Beckmann MW; Fasching PA
Curr Opin Obstet Gynecol; 2017 Feb; 29(1):4-11. PubMed ID: 28002265
[TBL] [Abstract][Full Text] [Related]
11. Do RANKL inhibitors (denosumab) affect inflammation and immunity?
Ferrari-Lacraz S; Ferrari S
Osteoporos Int; 2011 Feb; 22(2):435-46. PubMed ID: 20571772
[TBL] [Abstract][Full Text] [Related]
12. [Control of bone resorption by RANKL-RANK system].
Harada S; Takahashi N
Clin Calcium; 2011 Aug; 21(8):1121-30. PubMed ID: 21814016
[TBL] [Abstract][Full Text] [Related]
13. Osteoprotegerin as a potential therapy for osteoporosis.
Hamdy NA
Curr Osteoporos Rep; 2005 Dec; 3(4):121-5. PubMed ID: 16303111
[TBL] [Abstract][Full Text] [Related]
14. Strontium ranelate inhibits key factors affecting bone remodeling in human osteoarthritic subchondral bone osteoblasts.
Tat SK; Pelletier JP; Mineau F; Caron J; Martel-Pelletier J
Bone; 2011 Sep; 49(3):559-67. PubMed ID: 21700005
[TBL] [Abstract][Full Text] [Related]
15. Heparin enhances osteoclastic bone resorption by inhibiting osteoprotegerin activity.
Irie A; Takami M; Kubo H; Sekino-Suzuki N; Kasahara K; Sanai Y
Bone; 2007 Aug; 41(2):165-74. PubMed ID: 17560185
[TBL] [Abstract][Full Text] [Related]
16. RANKL inhibition for the management of patients with benign metabolic bone disorders.
Anastasilakis AD; Toulis KA; Polyzos SA; Terpos E
Expert Opin Investig Drugs; 2009 Aug; 18(8):1085-102. PubMed ID: 19558335
[TBL] [Abstract][Full Text] [Related]
17. Interleukin-20 differentially regulates bone mesenchymal stem cell activities in RANKL-induced osteoclastogenesis through the OPG/RANKL/RANK axis and the NF-κB, MAPK and AKT signalling pathways.
Meng B; Wu D; Cheng Y; Huang P; Liu Y; Gan L; Liu C; Cao Y
Scand J Immunol; 2020 May; 91(5):e12874. PubMed ID: 32090353
[TBL] [Abstract][Full Text] [Related]
18. Receptor activator of nuclear factor-κB ligand (RANKL)/RANK/osteoprotegerin system in bone and other tissues (review).
Liu W; Zhang X
Mol Med Rep; 2015 May; 11(5):3212-8. PubMed ID: 25572286
[TBL] [Abstract][Full Text] [Related]
19. [The OPG/RANKL/RANK system and bone resorptive disease].
Liu JZ; Ji ZL; Chen SM
Sheng Wu Gong Cheng Xue Bao; 2003 Nov; 19(6):655-60. PubMed ID: 15971575
[TBL] [Abstract][Full Text] [Related]
20. Skeletal and extraskeletal actions of denosumab.
Sinningen K; Tsourdi E; Rauner M; Rachner TD; Hamann C; Hofbauer LC
Endocrine; 2012 Aug; 42(1):52-62. PubMed ID: 22581255
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]